Our results showed that pre-treatment with necroptosis inhibitor Necrostatin-1 significantly compromised cisplatin-reduced cell viability in Skp2-knockdown (Fig. 7b) and SZL P1-41-treated (Fig. 7c) A549R cells, suggesting that the necroptosis mechanism could be involved in NSCLC cells’ resistance to cisplatin. Here, SKP2 is linked to non-small cell lung carcinoma.